ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2018
Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis.Clinical nuclear medicine · 2026Article
- Advanced Pulmonary Sarcoidosis: Treatment and Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Sarcoidosis-Associated Pulmonary Hypertension.Medicina (Kaunas, Lithuania) · 2025Review
- Emerging multimodality imaging techniques for the pulmonary circulation.The European respiratory journal · 2024Review
- Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension-A Challenging Mystery.Diagnostics (Basel, Switzerland) · 2023Review
- Sarcoidosis-associated pulmonary fibrosis: joining the dots.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- From Karl Wurm and Guy Scadding's staging toFrontiers in medicine · 2023Article
- Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches.Frontiers in medicine · 2022Review
- Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.Frontiers in immunology · 2020Review
- Quantification of pulmonary disease activity in sarcoidosis measured withEJNMMI research · 2019Article
- Hybrid Imaging in Head and Neck Sarcoidosis.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently FDG PET/CT is used as a tool for detection of active sites of sarcoidosis. Routine clinical practice relies on qualitative assessment with visual interpretation. When semi quantitatively expressed, e.g. for scientific purposes, this often leads to dichotomous "positive" or "negative" results. Metabolic activity in the lungs or mediastinum can also be expressed by SUVmax, but this measure is based only on the intensity of a single voxel. Likely for this reason these parameters show poor correlation with variables such as serum biomarkers and suboptimally predict clinical response to treatment. The current study focusses on new volumetric quantification methods for FDG PET/CT. Specifically the percentage of lung volume with increased metabolic activity, "%SUV-high", and the average metabolic activity in the lung "SUVmean", shows significantly better correlation with conventional biomarkers for disease activity than PET dichotomous and SUVmax. Our proposed quantification method needs subsequent and larger studies, however it may open new possibilities for future quantitative research in lung inflammation, and improve precision medicine in sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.